New anti-inflammatory drugs!

On December 17, Skyline Therapeutics Co.

This strategic cooperation will mainly use Jiutian Bio's comprehensively integrated AAV gene therapy R&D and production system, including its independent research and development of innovative viral vector design and construction technology and advanced production capabilities, aimed at genetic dilated cardiomyopathy ( DCM) to develop innovative gene therapies

Dilated cardiomyopathy is a group of serious cardiovascular diseases with progressive development, so far there is no effective targeted treatment

Public information shows that Jiutian Bio is an innovative gene and cell therapy company dedicated to the research, development and production of breakthrough gene and cell therapy

According to the agreement reached between the two parties, Jiutian Bio will cooperate with BioMarin to conduct comprehensive new drug research and development and advance the project to the new drug clinical trial application (IND) stage

In order to support Jiutian Bio's research and development of the cooperative project, BioMarin will pay Jiutian Bio a down payment, including the down payment and BioMarin's equity investment in Jiutian Bio

Reference materials:

[1]Givertz MM, Mann DL.

[2]Bozkurt B, Colvin M, Cook J, et al.

[3]Prevalence of rare diseases: Bibliographic data, Orphanet Report Series, Rare Diseases collection, January 2021, Number 1: Diseases listed in alphabetical order.

[4]Miura K, Nakagawa H, Morikawa Y, et al.

[5]Huang GY, Gao H, Meng XG.

[6]Jing Zhong, Li-Ping Li, Jian-Feng Zhou and Yong-He Ding (November 5th 2020).